Compile Data Set for Download or QSAR
Report error Found 218 with Last Name = 'carniato' and Initial = 'd'
LigandPNGBDBM29840(spiro-carboxamide scaffold, 13)
Affinity DataIC50: 0.5nMpH: 7.4 T: 2°CAssay Description:11beta-HSD1 enzyme activity was assessed in buffer containing a substrate mixture cortisone/NADPH in the presence of test compound. Reaction was init...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2009
Entry Details Article
PubMed
LigandPNGBDBM29839(spiro-carboxamide scaffold, 12)
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:11beta-HSD1 enzyme activity was assessed in buffer containing a substrate mixture cortisone/NADPH in the presence of test compound. Reaction was init...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101773((S)-2-(Naphthalene-1-sulfonylamino)-3-({5-[2-(1,4,...)
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101755((S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-{[5-(...)
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101766((S)-2-Ethenesulfonylamino-3-({5-[2-(1,4,5,6-tetrah...)
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101759((S)-2-(4-Chloro-benzenesulfonylamino)-3-({5-[2-(1,...)
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101753((S)-2-(4-Isopropyl-benzenesulfonylamino)-3-({5-[2-...)
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101768((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101763((S)-2-(3-Chloro-propane-1-sulfonylamino)-3-({5-[2-...)
Affinity DataIC50: 2nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101770((S)-2-(Biphenyl-4-sulfonylamino)-3-({5-[2-(1,4,5,6...)
Affinity DataIC50: 3nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101779((S)-2-(Quinoline-8-sulfonylamino)-3-({5-[2-(1,4,5,...)
Affinity DataIC50: 3nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101769((S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-({5-[2...)
Affinity DataIC50: 3nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM29834(spiro-carboxamide scaffold, 7)
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:11beta-HSD1 enzyme activity was assessed in buffer containing a substrate mixture cortisone/NADPH in the presence of test compound. Reaction was init...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101772((S)-2-Chloromethanesulfonylamino-3-({5-[2-(1,4,5,6...)
Affinity DataIC50: 4nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM50390701(CHEMBL2070229)
Affinity DataIC50: 4nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as conversion of cortisone to cortisol level after 150 mins by HTR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/8/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101771((S)-2-(Propane-1-sulfonylamino)-3-({5-[2-(1,4,5,6-...)
Affinity DataIC50: 4nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101764((S)-2-(Butane-1-sulfonylamino)-3-({5-[2-(1,4,5,6-t...)
Affinity DataIC50: 4nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM50390710(CHEMBL2070319)
Affinity DataIC50: 5nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as conversion of cortisone to cortisol level after 150 mins by HTR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/8/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101754((S)-2-Methanesulfonylamino-3-({5-[2-(1,4,5,6-tetra...)
Affinity DataIC50: 5nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101751((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)
Affinity DataIC50: 5nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101753((S)-2-(4-Isopropyl-benzenesulfonylamino)-3-({5-[2-...)
Affinity DataIC50: 6nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor (Vn/293) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM29833(spiro-carboxamide scaffold, 6)
Affinity DataIC50: 6nMpH: 7.4 T: 2°CAssay Description:11beta-HSD1 enzyme activity was assessed in buffer containing a substrate mixture cortisone/NADPH in the presence of test compound. Reaction was init...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/1/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101765((2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(5-{2-[(1,4...)
Affinity DataIC50: 7nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM50390703(CHEMBL2070231)
Affinity DataIC50: 7nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as conversion of cortisone to cortisol level after 150 mins by HTR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/8/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101768((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)
Affinity DataIC50: 7nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor (Vn/293) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM50294783(3,3-Dimethyl-pentanedioic acid(5-carbamoyl-adamant...)
Affinity DataIC50: 8nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as cortisol level after 150 mins by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2010
Entry Details Article
PubMed
LigandPNGBDBM50294781(N-Adamantan-2-yl-4-(3-isopropyl-[1,2,4]oxadiazol-5...)
Affinity DataIC50: 8nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as cortisol level after 150 mins by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2010
Entry Details Article
PubMed
LigandPNGBDBM50294764(3,3-Dimethyl-pentanedioic acid cyclopropylamide(5-...)
Affinity DataIC50: 8nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as cortisol level after 150 mins by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2010
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101767(3-Benzo[1,3]dioxol-5-yl-3-{[5-((E)-3-guanidino-3-o...)
Affinity DataIC50: 8nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM50294767(N-Adamantan-2-yl-2-{1-[(2-methoxy-phenylcarbamoyl)...)
Affinity DataIC50: 9nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as cortisol level after 150 mins by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2010
Entry Details Article
PubMed
LigandPNGBDBM50294771(N-Adamantan-2-yl-2-[1-(isobutylcarbamoyl-methyl)-c...)
Affinity DataIC50: 9nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as cortisol level after 150 mins by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2010
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50403867(CHEMBL2115098)
Affinity DataIC50: 9nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101770((S)-2-(Biphenyl-4-sulfonylamino)-3-({5-[2-(1,4,5,6...)
Affinity DataIC50: 9nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta-3 integrin by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)
Affinity DataIC50: 10nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor (Vn/293) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Target11-beta-hydroxysteroid dehydrogenase 1(Mouse)
Merck Serono

Curated by ChEMBL
LigandPNGBDBM50294783(3,3-Dimethyl-pentanedioic acid(5-carbamoyl-adamant...)
Affinity DataIC50: 10nMAssay Description:Inhibition of 11beta-HSD1 in mouse liver microsomeMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2010
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101752(3-Benzo[1,3]dioxol-5-yl-3-{[5-(3-guanidino-3-oxo-p...)
Affinity DataIC50: 10nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM50390702(CHEMBL2070230)
Affinity DataIC50: 10nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as conversion of cortisone to cortisol level after 150 mins by HTR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/8/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101760((S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-{[5-(...)
Affinity DataIC50: 10nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101761((S)-3-({5-[2-(1,4,5,6-Tetrahydro-pyrimidin-2-ylcar...)
Affinity DataIC50: 11nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta-3 integrin by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101759((S)-2-(4-Chloro-benzenesulfonylamino)-3-({5-[2-(1,...)
Affinity DataIC50: 12nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor (Vn/293) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM50390709(CHEMBL2070318)
Affinity DataIC50: 12nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as conversion of cortisone to cortisol level after 150 mins by HTR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/8/2013
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101769((S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-({5-[2...)
Affinity DataIC50: 12nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor (Vn/293) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM50294780(N-Adamantan-2-yl-4-(3-cyclopropyl-[1,2,4]oxadiazol...)
Affinity DataIC50: 12nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as cortisol level after 150 mins by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2010
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101773((S)-2-(Naphthalene-1-sulfonylamino)-3-({5-[2-(1,4,...)
Affinity DataIC50: 13nMAssay Description:Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor (Vn/293) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM50294770(N-Adamantan-2-yl-2-(1-{[(pyridin-2-ylmethyl)-carba...)
Affinity DataIC50: 16nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as cortisol level after 150 mins by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2010
Entry Details Article
PubMed
TargetIntegrin alpha-V/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101758(3-Benzo[1,3]dioxol-5-yl-3-{[5-(2-guanidinocarbonyl...)
Affinity DataIC50: 16nMAssay Description:Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
LigandPNGBDBM50294765(N-Adamantan-2-yl-2-{1-[(4-fluoro-phenylcarbamoyl)-...)
Affinity DataIC50: 17nMAssay Description:Inhibition of human recombinant 11beta-HSD1 expressed in Escherichia coli assessed as cortisol level after 150 mins by HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2010
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101753((S)-2-(4-Isopropyl-benzenesulfonylamino)-3-({5-[2-...)
Affinity DataIC50: 17nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta-3 integrin by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetIntegrin alpha-IIb/beta-3(Human)
Aventis Pharma Deutschland

Curated by ChEMBL
LigandPNGBDBM50101763((S)-2-(3-Chloro-propane-1-sulfonylamino)-3-({5-[2-...)
Affinity DataIC50: 17nMAssay Description:Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta-3 integrin by 50%More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
Displayed 1 to 50 (of 218 total ) | Next | Last >>
Jump to: